S 213571

Drug Profile

S 213571

Latest Information Update: 02 Sep 1998

Price : $50

At a glance

  • Originator Servier
  • Class Anxiolytics
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders

Most Recent Events

  • 02 Sep 1998 No-Development-Reported for Anxiety disorders in France (Unknown route)
  • 15 Feb 1996 New profile
  • 15 Feb 1996 Preclinical development for Anxiety disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top